^
    Back
    Association details:
    Biomarker:MAP2K1 K57E
    Cancer:Melanoma
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

    Excerpt:
    MEK1K57E and MEK2F57C confer melanoma cell resistance to dabrafenib.
    DOI:
    10.1158/1078-0432.CCR-13-3122